Literature DB >> 21118907

Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation.

Tomonori Iyoda1, Maki Ushida, Yukino Kimura, Kento Minamino, Akiko Hayuka, Shoichi Yokohata, Hiromi Ehara, Kayo Inaba.   

Abstract

Vα14 TCR expressing invariant NK T (iNKT) cells recognize α-galactosylceramide (αGC)/CD1d complex and produce large amounts of various cytokines before the onset of the adaptive immunity. After stimulation with a high dose (2-5 μg) of αGC in vivo, iNKT cells in the spleen and liver become anergic in terms of the proliferation and cytokine production to subsequent stimulation. In this study, we monitor how iNKT anergy is induced. Anergized iNKT cells dramatically reduced the expression of IL-2Rα, and exogenous IL-2 restored the ability to proliferate and produce IL-4 but not to produce IFN-γ. Anergized iNKT cells expressed high levels of programmed death-1 (PD-1). However, iNKT cells in PD-1-deficient mice became anergic as a result of αGC injection, as do normal mice. Furthermore, anti-PD-1 blocking mAb was unable to restore their responsiveness. When iNKT cells were stimulated with immobilized anti-CD3 in the presence or absence of anti-CD28, they produced cytokines in a dose-dependent manner. Unlike in naive CD4 T cells, the strong TCR-mediated signaling with co-stimulation renders them anergic to any subsequent stimulation with αGC and spleen dendritic cells (DCs). Moreover, iNKT cells also became anergic after stimulation with phorbol-12-myristate-13-acetate + ionophore. Finally, the injection of αGC-pulsed DCs was more potent in inducing anergy than B cells. These results indicate that strong TCR-mediated activation with co-stimulation provides signals that induce the anergic state in iNKT cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21118907     DOI: 10.1093/intimm/dxq444

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  19 in total

1.  IL-10-producing NKT10 cells are a distinct regulatory invariant NKT cell subset.

Authors:  Duygu Sag; Petra Krause; Catherine C Hedrick; Mitchell Kronenberg; Gerhard Wingender
Journal:  J Clin Invest       Date:  2014-07-25       Impact factor: 14.808

2.  Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition.

Authors:  Mérédis Favreau; Koen Venken; Sylvia Faict; Ken Maes; Kim De Veirman; Elke De Bruyne; Xavier Leleu; Louis Boon; Dirk Elewaut; Karin Vanderkerken; Eline Menu
Journal:  Haematologica       Date:  2017-04-06       Impact factor: 9.941

Review 3.  Engaging Natural Killer T Cells as 'Universal Helpers' for Vaccination.

Authors:  Mary Speir; Ian F Hermans; Robert Weinkove
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

Review 4.  T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.

Authors:  Z Wu; N V Cheung
Journal:  Pharmacol Ther       Date:  2017-08-20       Impact factor: 12.310

5.  Gene expression analysis of whole blood, peripheral blood mononuclear cells, and lymphoblastoid cell lines from the Framingham Heart Study.

Authors:  Roby Joehanes; Andrew D Johnson; Jennifer J Barb; Nalini Raghavachari; Poching Liu; Kimberly A Woodhouse; Christopher J O'Donnell; Peter J Munson; Daniel Levy
Journal:  Physiol Genomics       Date:  2011-11-01       Impact factor: 3.107

6.  The Protein Phosphatase Shp1 Regulates Invariant NKT Cell Effector Differentiation Independently of TCR and Slam Signaling.

Authors:  Mayra Cruz Tleugabulova; Meng Zhao; Irene Lau; Meggie Kuypers; Clarissa Wirianto; Juan Mauricio Umaña; Qiaochu Lin; Mitchell Kronenberg; Thierry Mallevaey
Journal:  J Immunol       Date:  2019-02-22       Impact factor: 5.422

Review 7.  mTOR and its tight regulation for iNKT cell development and effector function.

Authors:  Wei Yang; Balachandra Gorentla; Xiao-Ping Zhong; Jinwook Shin
Journal:  Mol Immunol       Date:  2015-08-04       Impact factor: 4.407

8.  Tuberous sclerosis 1 promotes invariant NKT cell anergy and inhibits invariant NKT cell-mediated antitumor immunity.

Authors:  Jinhong Wu; Jinwook Shin; Danli Xie; Hongxia Wang; Jimin Gao; Xiao-Ping Zhong
Journal:  J Immunol       Date:  2014-02-14       Impact factor: 5.422

9.  β-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergy.

Authors:  Jessica J O'Konek; Shingo Kato; Satomi Takao; Liat Izhak; Zheng Xia; Petr Illarionov; Gurdyal S Besra; Masaki Terabe; Jay A Berzofsky
Journal:  Clin Cancer Res       Date:  2013-06-26       Impact factor: 12.531

10.  CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses.

Authors:  Stéphanie Corgnac; Rachel Perret; Laurent Derré; Lianjun Zhang; Kathrin Stirnemann; Maurice Zauderer; Daniel E Speiser; Jean-Pierre Mach; Pedro Romero; Alena Donda
Journal:  Cancer Immunol Immunother       Date:  2012-12-15       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.